Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Articles|August 23, 2022
Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics
This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."
Advertisement
Advertisement
Related to this article
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Defining Treatment-Resistant Depression In Adults
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
4
Closing the Diagnostic Gap in Dementia With Blood-Based Biomarkers
5